Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials. The HIV p24 antigen levels decreased from a baseline value of 199 +/- 236 (mean +/- SD) and 140 pg/mL (median) to 106 +/- 218 and 28 pg/mL after 14 days of foscarnet induction therapy (60 mg/kg every 8 h). During chronic foscarnet maintenance, there was a sustained decrease in mean HIV p24 antigen levels below pre-foscarnet therapy baseline concentrations for a median of 16 weeks after foscarnet induction. These results provide evidence for a sustained clinical antiretroviral effect of chronic foscarnet maintenance therapy, consistent with a recent report that foscarnet-treated AIDS patients live longer than ganciclovir-treated patients.
Reddy
M M
MM
AIDS Clinical Trials Unit, St. Luke's/Roosevelt Hospital Center, New York, NY 10019.
Grieco
M H
MH
McKinley
G F
GF
Causey
D M
DM
van der Horst
C M
CM
Parenti
D M
DM
Hooton
T M
TM
Davis
R B
RB
Jacobson
M A
MA
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood* / Q000150:complications; D000328:Adult; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D017245:Foscarnet; D016655:HIV Core Protein p24 / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012173:Retinitis / Q000150:complications / Q000188:drug therapy*; D015215:Zidovudine / Q000627:therapeutic use
D016655:HIV Core Protein p24; D017245:Foscarnet; D015215:Zidovudine; D010746:Phosphonoacetic Acid